Cargando...
Discovery of inhibitors that overcome the G1202R ALK Resistance Mutation
The treatment of patients with advanced non-small cell lung cancer (NSCLC) harboring chromosomal rearrangements of anaplastic lymphoma kinase (ALK) has been revolutionized by the development of crizotinib, a small molecule inhibitor of ALK, ROS1, and MET. However, resistance to crizotinib inevitably...
Gardado en:
| Publicado en: | J Med Chem |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
2015
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4907642/ https://ncbi.nlm.nih.gov/pubmed/26568289 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1021/acs.jmedchem.5b01136 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|